Clinical Trial

Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 4, 2025 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This prospective, single-arm, multicenter clinical study aims to enroll 30 frail elderly patients with Non-GCB DLBCL. This study is to evaluate the preliminary efficacy and safety of the combination of Polatuzumab, Rituximab, and orelabrutinib in this population. The primary endpoint is CR rate after induction therapy.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06530511
Lead Sponsor Affiliated Hospital of Nantong University
Conditions Diffuse Large B Cell Lymphoma
Enrollment 30 participants
Start Date 2024-08-01
Primary Completion 2026-02-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-04